| Name | Title | Contact Details |
|---|---|---|
Nir Naor |
Chief Financial Officer | Profile |
Jens Kemp |
Chief Marketing Officer | Profile |
Jens Schroeder Kemp |
chief marketing officer | Profile |
Sameer Paranjpe |
Sr. Director New Product Development and Program Management | Profile |
Isabela Zimmermann Rollin |
R&D Intern | Profile |
LigoCyte Pharmaceuticals is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telstar is a Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProThera Biologics, LLC (Main) is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met.